Cythemias
News
FDA approves JAK inhibitor momelotinib for myelofibrosis with anemia
Momelotinib is the fourth JAK inhibitor approved by the FDA to treat the anemia that often accompanies myelofibrosis, a rare form of blood cancer...
Conference Coverage
PV: Novel rusfertide shows ‘impressive’ efficacy
The novel synthetic form of liver hormone hepcidin represents a “paradigm shift” in polycythemia vera treatment, allowing patients to avoid the...
Feature
EHA and TIF explore how COVID-19 is affecting thalassemia and SCD patients
Conference Coverage
BET inhibitor exhibits activity in myelofibrosis
ORLANDO - Responses were best among transfusion-dependent patients who received CPI-0610 and ruxolitinib.
Conference Coverage
Navitoclax may overcome ruxolitinib resistance in MF
ORLANDO – Navitoclax plus ruxolitinib decreased spleen volume, reduced bone marrow fibrosis, and improved total symptom scores in patients with...
News
FDA approves fedratinib for myelofibrosis
Fedratinib is approved to treat adults with intermediate-2 or high-risk primary or secondary myelofibrosis.
Conference Coverage
Back to the drawing board for MPN combo
NEWPORT BEACH, CALIF. – Ruxolitinib plus decitabine won’t proceed to a phase 3 trial for the treatment of accelerated or blast phase...
News
Long-acting interferon recommended for PV
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for ropeginterferon alfa-2b (...
News
Inhibitor can improve symptoms of systemic mastocytosis
SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers. Patients treated with...
News
FDA clears portable hematology analyzer
The U.S.
News
Underused PV treatments save lives, doc says
Researchers have found evidence to suggest that phlebotomy and hydroxyurea (HU) provide real-world benefits for older patients with polycythemia...